BR112017022958A2 - métodos para tratamento de câncer com inibidor da via da stat3 e inibidor de quinase - Google Patents

métodos para tratamento de câncer com inibidor da via da stat3 e inibidor de quinase

Info

Publication number
BR112017022958A2
BR112017022958A2 BR112017022958A BR112017022958A BR112017022958A2 BR 112017022958 A2 BR112017022958 A2 BR 112017022958A2 BR 112017022958 A BR112017022958 A BR 112017022958A BR 112017022958 A BR112017022958 A BR 112017022958A BR 112017022958 A2 BR112017022958 A2 BR 112017022958A2
Authority
BR
Brazil
Prior art keywords
methods
inhibitor
treating cancer
stat3 pathway
kinase inhibitor
Prior art date
Application number
BR112017022958A
Other languages
English (en)
Portuguese (pt)
Inventor
J Li Chiang
Rogoff Harry
Huang Janet
Li Youzhi
Gao Yuan
Original Assignee
Boston Biomedical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston Biomedical Inc filed Critical Boston Biomedical Inc
Publication of BR112017022958A2 publication Critical patent/BR112017022958A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112017022958A 2015-04-27 2016-04-26 métodos para tratamento de câncer com inibidor da via da stat3 e inibidor de quinase BR112017022958A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562153385P 2015-04-27 2015-04-27
PCT/US2016/029328 WO2016176190A1 (en) 2015-04-27 2016-04-26 Methods for treating cancer with a stat3 pathway inhibitor and kinase inhibitor

Publications (1)

Publication Number Publication Date
BR112017022958A2 true BR112017022958A2 (pt) 2018-07-17

Family

ID=56081544

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017022958A BR112017022958A2 (pt) 2015-04-27 2016-04-26 métodos para tratamento de câncer com inibidor da via da stat3 e inibidor de quinase

Country Status (16)

Country Link
US (1) US20180250261A1 (cg-RX-API-DMAC7.html)
EP (1) EP3288552A1 (cg-RX-API-DMAC7.html)
JP (2) JP2018514557A (cg-RX-API-DMAC7.html)
KR (1) KR20170141716A (cg-RX-API-DMAC7.html)
CN (1) CN107683137A (cg-RX-API-DMAC7.html)
AU (1) AU2016255034A1 (cg-RX-API-DMAC7.html)
BR (1) BR112017022958A2 (cg-RX-API-DMAC7.html)
CA (1) CA2983468A1 (cg-RX-API-DMAC7.html)
EA (1) EA201792320A1 (cg-RX-API-DMAC7.html)
HK (1) HK1252172A1 (cg-RX-API-DMAC7.html)
IL (1) IL255023A0 (cg-RX-API-DMAC7.html)
MX (1) MX2017013816A (cg-RX-API-DMAC7.html)
PH (1) PH12017501882A1 (cg-RX-API-DMAC7.html)
SG (1) SG11201708506QA (cg-RX-API-DMAC7.html)
TW (1) TW201713329A (cg-RX-API-DMAC7.html)
WO (1) WO2016176190A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2190429B1 (en) 2007-09-10 2016-04-20 Boston Biomedical, Inc. A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors
US20160030384A1 (en) 2013-04-09 2016-02-04 Boston Biomedical, Inc. 2-acetylnaphtho[2,3-b]furan -4,9-dione for use on treating cancer
WO2018005444A2 (en) * 2016-06-28 2018-01-04 Boston Biomedical, Inc. Methods for treating cancer
CA3045306A1 (en) 2016-11-29 2018-06-07 Boston Biomedical, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
JP2020520923A (ja) 2017-05-17 2020-07-16 ボストン バイオメディカル, インコーポレイテッド がんを処置するための方法
WO2022178957A1 (zh) * 2021-02-25 2022-09-01 毕庶壮 Napabucasin的制药用途
CN116173004A (zh) * 2021-11-26 2023-05-30 上海交通大学附属瑞金医院 硝呋齐特在制备用于预防或治疗肾上腺皮质癌的药物中的用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2736177A1 (en) * 2007-09-06 2009-03-12 Boston Biomedical, Inc. Compositions of kinase inhibitors and their use for treatment of cancer and other diseases related to kinases
EP2190429B1 (en) 2007-09-10 2016-04-20 Boston Biomedical, Inc. A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors
US20160030384A1 (en) * 2013-04-09 2016-02-04 Boston Biomedical, Inc. 2-acetylnaphtho[2,3-b]furan -4,9-dione for use on treating cancer

Also Published As

Publication number Publication date
AU2016255034A1 (en) 2017-11-02
EA201792320A1 (ru) 2018-02-28
JP2018514557A (ja) 2018-06-07
JP2021121629A (ja) 2021-08-26
IL255023A0 (en) 2017-12-31
CN107683137A (zh) 2018-02-09
SG11201708506QA (en) 2017-11-29
WO2016176190A1 (en) 2016-11-03
MX2017013816A (es) 2018-11-12
CA2983468A1 (en) 2016-11-03
EP3288552A1 (en) 2018-03-07
PH12017501882A1 (en) 2018-03-05
KR20170141716A (ko) 2017-12-26
US20180250261A1 (en) 2018-09-06
TW201713329A (zh) 2017-04-16
HK1252172A1 (zh) 2019-05-17

Similar Documents

Publication Publication Date Title
MX2020011745A (es) Terapias genicas para los trastornos lisosomales.
EA202191051A1 (ru) Ингибитор аврора-киназы a для применения для лечения нейробластомы
PH12017501882A1 (en) Methods for treating cancer with a stat3 pathway inhibitor and kinase inhibitor
EA201792116A1 (ru) Ингибитор янус-киназы
CO2018008761A2 (es) Derivados de maitansinoide, conjugados de los mismos métodos de uso
MX374439B (es) Compuesto de piridona como inhibidor de c-met
EA201890307A1 (ru) Индазольные и азаиндазольные соединения как ингибиторы irak-4
ECSP18040250A (es) Composiciones y métodos para inhibir la actividad arginasa
EA201891024A1 (ru) Соединения-ингибиторы tank-связывающей киназы
BR112019001607A2 (pt) inibidores macrocíclicos de quinases
BR112016028288A2 (pt) ?composto, composição farmacêutica, métodos para tratamento de um indivíduo com uma doença ou condição e para inibir a quinase, e, uso de um composto?
CY1122024T1 (el) Ενωσεις αναστολης σηματοδοτησης μονοπατιου notch
BR112016024057A2 (pt) inibidores de quinases heterocíclicos
MX2015005536A (es) Tratamiento de canceres utilizando moduladores de las isoformas de pi3 cinasa.
NI201800042A (es) Nuevos derivados de pirrolo[2,3-d]pirimidina como inhibidores duales de dyrk1/clk1
MX2019007243A (es) Inhibidores de ectonucleotidasa y metodos de uso de los mismos.
CL2015002932A1 (es) Inhibidores de proteína quinasa
CR20150472A (es) USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRANSTORNOS RELACIONADOS CON LA PI3Kd
HRP20260058T1 (hr) Dozni oblici za tyk2 inhibitore
BR112016007467A2 (pt) compostos heterocíclicos e usos dos mesmos
CL2021000292A1 (es) Benzimidazoles sustituidos como inhibidores de pad4.
MX2019007339A (es) Compuestos de pirazolopirimidina y metodos de uso de los mismos.
MX389545B (es) Compuestos terapeuticos y composiciones para el tratamiento de trastornos sociales y trastornos de uso de sustancias.
BR112019020421A8 (pt) Derivados de 2-oxo- tiazóis como inibidores de a2a e compostos para uso no tratamento de cânceres
CY1123576T1 (el) Συμπυκνωμενα παραγωγα θειοφαινιου χρησιμα ως αναστολεις του napi-iib

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]